Formulation and in vivo evaluation of ocular insert containing phenylephrine and tropicamide.

A Gelfoam based ocular device containing 1.7 mg of phenylephrine and 0.6 mg of tropicamide was formulated and evaluated for pupillary dilation in rabbits. The manufacturing procedure is fairly simple and the required excipients are inexpensive. The in vivo results show that the mydriatic response produced by the proposed device is larger and longer lasting than that produced by eyedrops with an equivalent amount of phenylephrine and tropicamide. The results reported in this study, along with those of previous studies, imply that Gelfoam(R) is a versatile drug carrier for either local or systemic drug delivery via the ophthalmic route.

[1]  S. Yalkowsky,et al.  Systemic delivery of insulin via an enhancer-free ocular device. , 1997, Journal of pharmaceutical sciences.

[2]  S. Yalkowsky,et al.  Effect of Brij-78 on systemic delivery of insulin from an ocular device. , 1997, Journal of pharmaceutical sciences.

[3]  S. Yalkowsky,et al.  Controlled delivery of pilocarpine. 2. In-vivo evaluation of Gelfoam® device , 1998 .

[4]  I. Kellaway,et al.  A novel ocular delivery system for phenylephrine hydrochloride , 1996 .

[5]  R. Rengstorff,et al.  Mydriatic and cycloplegic drugs: a review of ocular and systemic complications. , 1982, American journal of optometry and physiological optics.

[6]  C. Hanna,et al.  Use of drugs in ointment for routine mydriasis. , 1977, Annals of ophthalmology.

[7]  A. Urtti,et al.  Roles of acid/base nature and molecular weight in drug release from matrices of gelfoam and monoisopropyl ester of poly(vinyl methyl ether-maleic anhydride). , 1998, Journal of controlled release : official journal of the Controlled Release Society.

[8]  R. Gray,et al.  Visual recovery using small dilating eye drops , 1992, The Journal of pharmacy and pharmacology.

[9]  N. Peppas,et al.  Design of ocular/lacrimal and nasal systems through analysis of drug administration and absorption , 1997 .

[10]  T. Ho,et al.  Maximal mydriasis evaluation in cataract surgery , 1992, Indian journal of ophthalmology.

[11]  N. P. O’Donnell,et al.  A comparison of the efficacy of tropicamide applied topically using a novel ophthalmic delivery system versus a phenylephrine-tropicamide drop preparation in insulin-independent diabetics , 1995, Eye.

[12]  L. Levine.  Mydriatic Effectiveness of Dilute Combinations of Phenylephrine and Tropicamide , 1982, American Journal of Optometry and Physiological Optics.

[13]  M. F. Saettone,et al.  Polymer effects on ocular bioavailability: the influence of different liquid vehicles on the mydriatic response of tropicamide in humans and in rabbits , 1984 .

[14]  J. Robinson,et al.  Bioadhesive polymers in peptide drug delivery. , 1990, Biomaterials.

[15]  S. Yalkowsky,et al.  Systemic delivery of melanotan II through the ocular route in rabbits. , 1997, Journal of pharmaceutical sciences.

[16]  M. Doughty,et al.  A pupillographic evaluation of a phenylephrine HCl 5%-tropicamide 0.8% combination mydriatic. , 1989, Journal of ocular pharmacology.

[17]  S. Yalkowsky,et al.  Ocular device for the controlled systemic delivery of insulin. , 1996, Journal of pharmaceutical sciences.

[18]  A. Henrick,et al.  Pupillary dilatation with single eyedrop mydriatic combinations. , 1980, American journal of ophthalmology.

[19]  N. Yüksel,et al.  The influence of drop size of cyclopentolate, phenylephrine and tropicamide on pupil dilatation and systemic side effects in infants. , 2009, Acta ophthalmologica Scandinavica.

[20]  M. F. Saettone,et al.  The effect of different ophthalmic vehicles on the activity of tropicamide in man , 1980, The Journal of pharmacy and pharmacology.

[21]  D. Battistutta,et al.  Comparative pupil dilation using phenylephrine alone or in combination with tropicamide. , 1998, Ophthalmology.